Core Viewpoint - The company and its subsidiary Hangzhou Danwei have recently obtained multiple medical device product registration certificates, enhancing their product offerings and market reach [1] Domestic Developments - Hangzhou Danwei's Mycoplasma pneumoniae nucleic acid detection kit (fluorescent PCR method) has been registered, with a validity period until January 18, 2031 [1] International Developments - The company has received registration certificates for several products, including the creatine kinase isoenzyme detection kit, in Brazil and the European Union, with varying validity periods [1] Product Portfolio Enhancement - The recent certifications supplement the company's pneumonia detection product series and improve the layout of time-resolved fluorescence immunochromatography products, expanding the sales regions [1] Sales Performance Outlook - Actual sales performance from these newly registered products cannot be predicted at this time [1]